Atenção: Todas as denúncias são sigilosas e sua identidade será preservada.
Os campos nome e e-mail são de preenchimento opcional
Metadados | Descrição | Idioma |
---|---|---|
Autor(es): dc.creator | Cerqueira, Adara Rodrigues Damasceno | - |
Autor(es): dc.creator | Fratelli, Caroline Ferreira | - |
Autor(es): dc.creator | Duarte, Ligia Canongia de Abreu Cardoso | - |
Autor(es): dc.creator | Pereira, Alexandre Sampaio Rodrigues | - |
Autor(es): dc.creator | Morais, Rafael Martins de | - |
Autor(es): dc.creator | Barra Sobrinho, Alaor | - |
Autor(es): dc.creator | Silva, Calliandra Maria de Souza | - |
Autor(es): dc.creator | Silva, Izabel Cristina Rodrigues da | - |
Autor(es): dc.creator | Oliveira, Jamila Reis de | - |
Data de aceite: dc.date.accessioned | 2024-07-22T13:09:51Z | - |
Data de disponibilização: dc.date.available | 2024-07-22T13:09:51Z | - |
Data de envio: dc.date.issued | 2021-07-28 | - |
Data de envio: dc.date.issued | 2021-07-28 | - |
Data de envio: dc.date.issued | 2019 | - |
Fonte completa do material: dc.identifier | https://repositorio.unb.br/handle/10482/41510 | - |
Fonte completa do material: dc.identifier | https://doi.org/10.1177/1724600820961787 | - |
Fonte completa do material: dc.identifier | https://orcid.org/0000-0002-0511-9452 | - |
Fonte: dc.identifier.uri | http://educapes.capes.gov.br/handle/capes/819359 | - |
Descrição: dc.description | Thyroid cancer is the most common endocrine cancer in the world. Noting that the NOS3 gene polymorphism interferes with nitric oxide production, this study aims to identify and analyze the NOS3 gene polymorphism in the intron 4 region in patients with papillary thyroid cancer. A case-control study was conducted with 31 papillary thyroid cancer patients of both genders who underwent thyroidectomy and treatment with sodium iodide radiopharmaceutical (131I) compared with 81 control patients. Through papillary thyroid cancer, the results were observed, compiled, and analyzed using SPSS version 25.0. The significance level of 5% was adopted. Genotypic frequencies of healthy subjects were in the Hardy-Weinberg equilibrium (P = 0.503). There was a significant genotypic difference between papillary thyroid cancer and healthy individuals (P <0.001). The BB genotype conferred a protective factor for papillary thyroid cancer (P <0.001, odds ratio (OR) 0.16; 95% confidence interval (CI) 0.06, 0.42), while the presence of the A allele appears to be a risk factor for papillary thyroid cancer (P <0.001, OR 3.54; 95% CI 1.86, 6.73). The intron 4 polymorphism of the NOS3 gene was associated with susceptibility to papillary thyroid cancer. Thus, future research into the effects of this polymorphism is essential. | - |
Descrição: dc.description | Faculdade UnB Ceilândia (FCE) | - |
Descrição: dc.description | Programa de Pós-Graduação em Ciências e Tecnologias em Saúde | - |
Formato: dc.format | application/pdf | - |
Publicador: dc.publisher | Sage | - |
Direitos: dc.rights | Acesso Aberto | - |
Direitos: dc.rights | Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). | - |
Palavras-chave: dc.subject | Polimorfismo (Genética) | - |
Palavras-chave: dc.subject | Tireóide - câncer | - |
Palavras-chave: dc.subject | Tireoidectomia | - |
Palavras-chave: dc.subject | Óxido nítrico | - |
Título: dc.title | The impact of NOS3 gene polymorphism on papillary thyroid cancer susceptibility in patients undergoing radioiodine therapy | - |
Aparece nas coleções: | Repositório Institucional – UNB |
O Portal eduCAPES é oferecido ao usuário, condicionado à aceitação dos termos, condições e avisos contidos aqui e sem modificações. A CAPES poderá modificar o conteúdo ou formato deste site ou acabar com a sua operação ou suas ferramentas a seu critério único e sem aviso prévio. Ao acessar este portal, você, usuário pessoa física ou jurídica, se declara compreender e aceitar as condições aqui estabelecidas, da seguinte forma: